A detailed history of Pfm Health Sciences, LP transactions in Uni Qure N.V. stock. As of the latest transaction made, Pfm Health Sciences, LP holds 274,540 shares of QURE stock, worth $1.76 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
274,540
Previous 274,540 -0.0%
Holding current value
$1.76 Million
Previous $1.43 Million 13.88%
% of portfolio
0.06%
Previous 0.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$4.82 - $6.93 $1.32 Million - $1.9 Million
274,540 New
274,540 $1.43 Million
Q2 2023

Aug 14, 2023

SELL
$11.12 - $22.2 $22.8 Million - $45.5 Million
-2,049,453 Reduced 97.13%
60,617 $694,000
Q1 2023

May 15, 2023

SELL
$18.7 - $23.07 $3.59 Million - $4.44 Million
-192,244 Reduced 8.35%
2,110,070 $42.5 Million
Q4 2022

Feb 14, 2023

SELL
$18.12 - $27.32 $1.65 Million - $2.49 Million
-90,997 Reduced 3.8%
2,302,314 $52.2 Million
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $2.66 Million - $4.01 Million
156,941 Added 7.02%
2,393,311 $44.9 Million
Q2 2022

Aug 15, 2022

BUY
$13.15 - $20.45 $22.4 Million - $34.8 Million
1,701,746 Added 318.31%
2,236,370 $41.7 Million
Q1 2022

May 16, 2022

BUY
$14.54 - $21.5 $7.77 Million - $11.5 Million
534,624 New
534,624 $9.66 Million
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $43 Million - $86.5 Million
-1,158,694 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $38.7 Million - $75.6 Million
983,940 Added 563.04%
1,158,694 $45.6 Million
Q2 2019

Aug 14, 2019

SELL
$52.76 - $82.19 $12.8 Million - $19.9 Million
-242,108 Reduced 58.08%
174,754 $13.7 Million
Q1 2019

May 15, 2019

BUY
$27.39 - $68.41 $11.4 Million - $28.5 Million
416,862 New
416,862 $24.9 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Pfm Health Sciences, LP Portfolio

Follow Pfm Health Sciences, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pfm Health Sciences, LP with notifications on news.